These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34283051)

  • 1. Differential Regulation of Lacto-/Neolacto- Glycosphingolipid Biosynthesis Pathway Reveals Transcription Factors as Potential Candidates in Triple-Negative Breast Cancer.
    Zeng R; Mohamed A; Khanna KK; Hill MM
    Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34283051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hallmarks of glycogene expression and glycosylation pathways in squamous and adenocarcinoma cervical cancer.
    Martinez-Morales P; Morán Cruz I; Roa-de la Cruz L; Maycotte P; Reyes Salinas JS; Vazquez Zamora VJ; Gutierrez Quiroz CT; Montiel-Jarquin AJ; Vallejo-Ruiz V
    PeerJ; 2021; 9():e12081. PubMed ID: 34540372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circular RNA hsa_circ_0044234 as distinct molecular signature of triple negative breast cancer: a potential regulator of GATA3.
    Darbeheshti F; Zokaei E; Mansoori Y; Emadi Allahyari S; Kamaliyan Z; Kadkhoda S; Tavakkoly Bazzaz J; Rezaei N; Shakoori A
    Cancer Cell Int; 2021 Jun; 21(1):312. PubMed ID: 34126989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of lacto/neolacto-glycolipids enhances the formation of glycolipid-enriched microdomains, facilitating B cell activation.
    Togayachi A; Kozono Y; Ikehara Y; Ito H; Suzuki N; Tsunoda Y; Abe S; Sato T; Nakamura K; Suzuki M; Goda HM; Ito M; Kudo T; Takahashi S; Narimatsu H
    Proc Natl Acad Sci U S A; 2010 Jun; 107(26):11900-5. PubMed ID: 20547865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC).
    Narrandes S; Huang S; Murphy L; Xu W
    BMC Cancer; 2018 Jan; 18(1):22. PubMed ID: 29301506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer molecular subtypes: from TNBC to QNBC.
    Hon JD; Singh B; Sahin A; Du G; Wang J; Wang VY; Deng FM; Zhang DY; Monaco ME; Lee P
    Am J Cancer Res; 2016; 6(9):1864-1872. PubMed ID: 27725895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
    Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
    Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative proteomics reveals stage-specific protein regulation of triple negative breast cancer.
    Lin Y; Lin L; Fu F; Wang C; Hu A; Xie J; Jiang M; Wang Z; Yang L; Guo R; Yang P; Shen H
    Breast Cancer Res Treat; 2021 Jan; 185(1):39-52. PubMed ID: 32920739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolite Profiling Reveals the Glutathione Biosynthetic Pathway as a Therapeutic Target in Triple-Negative Breast Cancer.
    Beatty A; Fink LS; Singh T; Strigun A; Peter E; Ferrer CM; Nicolas E; Cai KQ; Moran TP; Reginato MJ; Rennefahrt U; Peterson JR
    Mol Cancer Ther; 2018 Jan; 17(1):264-275. PubMed ID: 29021292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Silico Analysis of Publicly Available Transcriptomic Data for the Identification of Triple-Negative Breast Cancer-Specific Biomarkers.
    Kaddoura R; Alqutami F; Asbaita M; Hachim M
    Life (Basel); 2023 Feb; 13(2):. PubMed ID: 36836779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unraveling the Genomic-Epigenomic Interaction Landscape in Triple Negative and Non-Triple Negative Breast Cancer.
    Wu J; Mamidi TKK; Zhang L; Hicks C
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma: comparison with GATA3 expression and PELP1's potential role in triple-negative breast carcinoma.
    Dang DN; Raj G; Sarode V; Molberg KH; Vadlamudi RK; Peng Y
    Hum Pathol; 2015 Dec; 46(12):1829-35. PubMed ID: 26428280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA-seq analysis identified hormone-related genes associated with prognosis of triple negative breast cancer.
    Chen F; Li Y; Qin N; Wang F; Du J; Wang C; Du F; Jiang T; Jiang Y; Dai J; Hu Z; Lu C; Shen H
    J Biomed Res; 2020 Jan; 34(2):129-138. PubMed ID: 32305967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.
    Barton VN; D'Amato NC; Gordon MA; Lind HT; Spoelstra NS; Babbs BL; Heinz RE; Elias A; Jedlicka P; Jacobsen BM; Richer JK
    Mol Cancer Ther; 2015 Mar; 14(3):769-78. PubMed ID: 25713333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Milk Protein Alpha-Casein Suppresses Triple Negative Breast Cancer Stem Cell Activity Via STAT and HIF-1alpha Signalling Pathways in Breast Cancer Cells and Fibroblasts.
    Garner KEL; Hull NJ; Sims AH; Lamb R; Clarke RB
    J Mammary Gland Biol Neoplasia; 2019 Sep; 24(3):245-256. PubMed ID: 31529195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes.
    McNamara KM; Yoda T; Nurani AM; Shibahara Y; Miki Y; Wang L; Nakamura Y; Suzuki K; Yang Y; Abe E; Hirakawa H; Suzuki T; Nemoto N; Miyashita M; Tamaki K; Ishida T; Brown KA; Ohuchi N; Sasano H
    Breast Cancer Res Treat; 2014 Jun; 145(2):281-93. PubMed ID: 24715382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulated GATA3/miR205-5p Axis Inhibits MFNG Transcription and Reduces the Malignancy of Triple-Negative Breast Cancer.
    Mugisha S; Di X; Wen D; Zhao Y; Wu X; Zhang S; Jiang H
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer.
    Krings G; Nystrom M; Mehdi I; Vohra P; Chen YY
    Hum Pathol; 2014 Nov; 45(11):2225-32. PubMed ID: 25150746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the androgen receptor in triple-negative breast cancer: current perspectives.
    Mina A; Yoder R; Sharma P
    Onco Targets Ther; 2017; 10():4675-4685. PubMed ID: 29033586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.